Entertainment

【skip the games findlay ohio】What Are Analysts Expecting From Senior plc (LON:SNR) In The Year Ahead?

字号+ 作者:how can homeaglow only charge $19 来源:Entertainment 2024-09-29 08:22:24 我要评论(0)

After Senior plc’s (LON:SNR) recent earnings announcement in June 2018, analyst forecasts appear to skip the games findlay ohio

After Senior plc’s (

LON:SNR

【skip the games findlay ohio】What Are Analysts Expecting From Senior plc (LON:SNR) In The Year Ahead?


) recent earnings announcement in June 2018,skip the games findlay ohio analyst forecasts appear to be pessimistic, with earnings expected to decline by -14% in the upcoming year. However, this pessimism is not unfounded, given the negative earnings growth rate over the past five years on average. With trailing-twelve-month net income at current levels of UK£60m, the consensus growth rate suggests that earnings will decline to UK£52m by 2020. In this article, I’ve outline a few earnings growth rates to give you a sense of the market sentiment for Senior in the longer term. Readers that are interested in understanding the company beyond these figures should

【skip the games findlay ohio】What Are Analysts Expecting From Senior plc (LON:SNR) In The Year Ahead?


research its fundamentals here

【skip the games findlay ohio】What Are Analysts Expecting From Senior plc (LON:SNR) In The Year Ahead?


.


View our latest analysis for Senior


What can we expect from Senior in the longer term?


The longer term expectations from the 6 analysts of SNR is tilted towards the positive sentiment. Since forecasting becomes more difficult further into the future, broker analysts generally project out to around three years. To reduce the year-on-year volatility of analyst earnings forecast, I’ve inserted a line of best fit through the expected earnings figures to determine the annual growth rate from the slope of the line.


LSE:SNR Future Profit January 2nd 19


From the current net income level of UK£60m and the final forecast of UK£74m by 2022, the annual rate of growth for SNR’s earnings is 13%. EPS reaches £0.17 in the final year of forecast compared to the current £0.14 EPS today. With a current profit margin of 5.9%, this movement will result in a margin of 6.3% by 2022.


Next Steps:


Future outlook is only one aspect when you’re building an investment case for a stock. For Senior, I’ve put together three key aspects you should look at:


Financial Health


: Does it have a healthy balance sheet? Take a look at our


free balance sheet analysis with six simple checks


on key factors like leverage and risk.


Valuation


: What is Senior worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The


intrinsic value infographic in our free research report


helps visualize whether Senior is currently mispriced by the market.


Other High-Growth Alternatives


: Are there other high-growth stocks you could be holding instead of Senior? Explore


our interactive list of stocks with large growth potential


to get an idea of what else is out there you may be missing!


To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.


The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at


[email protected]


.


View comments


1.本站遵循行业规范,任何转载的稿件都会明确标注作者和来源;2.本站的原创文章,请转载时务必注明文章作者和来源,不尊重原创的行为我们将追究责任;3.作者投稿可能会经我们编辑修改或补充。

相关文章
  • INTRUSION Inc. Welcomes Experienced Chief Financial Officer, Franklin Byrd

    INTRUSION Inc. Welcomes Experienced Chief Financial Officer, Franklin Byrd

    2024-09-29 07:46

  • 15 Biggest Steel Companies In The World

    15 Biggest Steel Companies In The World

    2024-09-29 07:22

  • BRIEF-Luye Pharma Announces Clinical Trial Application Of Biological Antibody LY09004 Accepted By NMPA In China

    BRIEF-Luye Pharma Announces Clinical Trial Application Of Biological Antibody LY09004 Accepted By NMPA In China

    2024-09-29 06:53

  • SoCoCare Receives 2013 TMC Labs Innovation Award

    SoCoCare Receives 2013 TMC Labs Innovation Award

    2024-09-29 06:37

网友点评